Table 1.
Activity of immune checkpoint inhibitors in clear-cell sRCC from subgroup analyses of phase 3 trials.
| Trials | Population | Agents | N | ORR | CRR | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|
| Keynote-426 | Intent-to-treat | pembrolizumab + axitinib | 51 | 59% | 13% | 8.4 months | NR |
| vs. | vs. | vs. | vs. | vs. | vs. | ||
| sunitinib | 54 | 32% | 2% | NR | NR | ||
| CheckMate-214 | IMDC poor or intermediate risk | nivolumab + ipilimumab | 60 | 57% | 18% | 8.4 months | 31.2 months |
| vs. | vs. | vs. | vs. | vs. | vs. | ||
| sunitinib | 52 | 19% | 0% | 4.9 months | 13.6 months | ||
| IMmotion151 | Intent-to-treat | atezolizumab + bevacizumab | 68 | 49% | 10% | 8.3 months | 21.7 months |
| vs. | vs. | vs. | vs. | vs. | vs. | ||
| sunitinib | 74 | 14% | 3% | 5.3 months | 15.4 months | ||
| JAVELIN Renal 101 | Intent-to-treat | avelumab + axitinib | 47 | 47% | 4% | 7.0 months | NA |
| vs. | vs. | vs. | vs. | vs. | |||
| sunitinib | 61 | 21% | 0% | 4.0 months |
Abbreviations: ORR: objective response rate, CRR: complete response rate, PFS: progression-free survival, OS: overall survival, NR: not reached, NA: not available, CPS: combined positive score.